Company: BDRX
Filing Date: 2025-01-28
Form Type: 424B3
Source: 0001214659-25-001409
Chunk: 9

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-01-28
Form: 424B3
Chunk 9
---
 targeting sites of disease by using either chemotherapeutic agents or immunotherapeutic agents. |

We are currently focused on our clinical stage
assets and there are no active research and development programs based on our drug delivery technologies.

Recent Developments

The Committed Equity Financing

On January 17, 2025, we entered into the Purchase Agreement withthe Selling Shareholder, pursuant to which we, subject to the restrictions and satisfaction of the conditions in the Purchase Agreement, have the right, but not the obligation, to sell tothe Selling Shareholder, andthe Selling Shareholder is obligated to purchase, up to $35.0 million of newly issued Depositary Shares. As consideration for the Seller Shareholder’s execution and delivery of the Purchase Agreement, we have agreed to pay to the Selling Shareholder a fee of $875,000 in cash, or the Commitment Fee, as described further herein.

| 4 |

We do not have a right to commence any sales of Depositary Shares tothe Selling Shareholder under the Purchase Agreement until the Commencement Date (as defined in the Purchase Agreement). Over the 36-month period from and after the Commencement Date (unless the Purchase Agreement is terminated earlier in accordance with its terms),the Selling Shareholder has no right to require us to sell any Depositary Shares tothe Selling Shareholder, butthe
Selling Shareholder is obligated to make purchases as we direct, subject to certain conditions. There are no upper limits on the price per share thatthe Selling Shareholder must pay for Depositary Shares. Actual sales of Depositary Shares tothe Selling Shareholder will depend on a variety of factors to be determined by us from time to time, including, among others, market conditions, the trading price of our Depositary Shares and determinations by us as to the appropriate sources of funding for us and our operations.

At any time from and after the Commencement Date, on any business day on which the previous business day’s closing sale price of Depositary Shares was equal to or greater than $1.00, or the Purchase Date, we may direct the Selling Shareholder to purchase a specified number of Depositary Shares, or a Fixed Purchase, not to exceed $200,000, at a purchase price equal to the lesser of 95% of (i) the daily volume weighted average price, or VWAP, of the Depositary Shares for the five trading days immediately preceding the applicable Purchase Date for such Fixed Purchase and (ii) the lowest sale price of a Deposit